Evaluating the Efficacy of XJH05 Ointment Compared to Calcipotriol in Treating Plaque Psoriasis A Prospective, Interventional Study

What This Trial Is About

Psoriasis is a chronic, recurrent inflammatory and systemic disease influenced by genetic and environmental factors, characterized mainly by scaly erythema or plaques. This trial evaluates the efficacy of a new small-molecule compound called XJH05 ointment in treating plaque psoriasis, the most common subtype affecting approximately 90% of patients. The study aims to provide evidence for XJH05 as a novel treatment that targets the interaction between lipocalin-2 and its receptor SLC22A17, which plays a key role in the diseases progression. Participants in the trial are randomly assigned to apply either the XJH05 ointment or calcipotriol ointment twice daily on the affected skin areas for 4 weeks. Each application uses a standardized amount of approximately 500 mg per fingertip, covering about two palm areas. The study includes screening, treatment, and follow-up phases, with photographs taken of affected areas at baseline and after 4 weeks to document changes and evaluate improvements in lesion severity and itch symptoms. During the study, participants attend scheduled clinic visits at baseline, weeks 2, 4, 8, and 12 to monitor treatment effects, safety, and tolerability. Researchers assess changes in psoriasis lesions using dermoscopy, evaluate Physician Global Assessment PGA scores, and record itch severity using numerical rating scales. Safety assessments include monitoring for local skin reactions and any adverse events. The study aims to improve understanding of XJH05 ointments impact on plaque psoriasis over a total participation period of up to 12 weeks.

A Prospective, Interventional, Exploratory Study Evaluating the Efficacy of Small-Molecule Compound XJH05 Ointment in the Treatment of Plaque Psoriasis